Korean pharmaceutical firms urged to brace for diverse R&D investment portfolios

Published: 2004-06-04 07:00:00

Updated: 2004-06-04 07:00:00

Amid depressed consumer demand and a slumping economy, Korean pharmaceutical firms plan to focus on a wide variety of R&D new drug projects, including first-generic version, bioequivalence-tested drugs and novel dosage forms so as to enhance research-based corporate images and competitive edge in...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK